Initial (phase I) clinical evidence indicates that a high dose of intranasal NPY reduces anxiety in individuals with PTSD (Sayed et al., 2018), and there is another active PTSD trial underway (NCT04071600). Here, NPY is linked to post-traumatic stress disorder.